Buy Gemtaz 1g - Gemcitabine Injection Online, Gemtaz 1g - Gemcitabine Injection Manufacturers

Wishlist(0)

Gemtaz 1g - Gemcitabine Injection

Gemtaz 1g is a potent chemotherapy medication used to treat several types of cancer, including lung, pancreatic, breast, ovarian, and bladder cancers. It inhibits the growth of cancer cells by interfering with their DNA synthesis.

Select your size:

1gm

Choose Quantity:

+ Add To Cart

Buy Now

Add to wishlist

Description Product Details

General Information:

Generic Name: Gemcitabine Hydrochloride

Brand Name: Gemtaz

Packing: Single-use vial

Strength: 1g (1000mg)

Manufacturer: Sun Pharmaceutical Industries Ltd.

Form: Lyophilized Powder for Injection

Category: Anticancer / Antimetabolite / Chemotherapy Agent

Product Intro:

Gemtaz 1g is a lyophilized powder form of Gemcitabine, a nucleoside analog used as a cytotoxic agent in cancer therapy. It is administered intravenously and often used as a single agent or in combination with other chemotherapeutic drugs depending on the type of cancer being treated.

Uses:

Gemtaz 1g is used in the treatment of:

Non-Small Cell Lung Cancer (NSCLC)
Pancreatic Cancer
Breast Cancer
Ovarian Cancer
Bladder Cancer
Biliary Tract Cancers (e.g., cholangiocarcinoma)

Storage Instructions:

Store below 25°C
Protect from moisture and direct light
After reconstitution, store the solution in a refrigerator (2°C–8°C) and use within 24 hours
Do not freeze the reconstituted solution

How it Works (Mechanism of Action):

Gemcitabine mimics a natural building block of DNA. When incorporated into DNA during replication, it causes cell cycle arrest and apoptosis (cell death). It also inhibits ribonucleotide reductase, reducing the number of nucleotides available for DNA synthesis, which is crucial for rapidly dividing cancer cells.

Side Effects:

Common Side Effects:

Fatigue
Nausea and vomiting
Fever and flu-like symptoms
Low white blood cell or platelet count
Mild skin rash

Severe Side Effects:

Pulmonary toxicity (interstitial pneumonitis)
Liver enzyme abnormalities
Hemolytic-uremic syndrome (rare)
Renal impairment
Severe myelosuppression

Dosage (Typical Recommended Dose):

Typically administered as 1000 mg/m² IV over 30 minutes on days 1, 8, and 15 of a 28-day cycle
Actual dose may vary based on patient’s body surface area (BSA), cancer type, and combination therapies
Gemtaz 1g provides flexible dosing in standard treatment protocols

Method of Administration:

Reconstitute the powder with sterile water for injection
Administer via slow intravenous infusion (usually over 30 minutes)
Only to be administered by trained healthcare professionals

Precautions:

Avoid in pregnancy and breastfeeding
Regular monitoring of blood counts, liver, and kidney function is required
Use effective contraception during and for several months after treatment
Avoid close contact with people recently vaccinated with live vaccines
Caution in patients with pre-existing pulmonary or renal conditions

Drug Interactions:

May increase toxicity when combined with cisplatin or capecitabine
May interact with warfarin – monitor INR levels closely
Avoid concurrent use with live vaccines due to risk of infection

Allergies:

Contraindicated in individuals with known hypersensitivity to Gemcitabine
Symptoms of allergic reactions include rash, hives, facial swelling, and difficulty breathing

Overdose Information:

Symptoms may include severe bone marrow suppression, organ dysfunction, and life-threatening complications
Immediate medical intervention and supportive care are required
No specific antidote exists

Missed Dose Instructions:

If a dose is missed, the doctor may adjust the treatment schedule
Do not self-administer or double dose without medical supervision
Report missed doses to the treating physician promptly

Additional Notes:

Stay well-hydrated before and after infusion to help with kidney function
Avoid alcohol and tobacco during treatment
Periodic imaging and lab tests may be required to assess effectiveness
Dispose of unused medicine and medical waste properly